← Human Trials & Peer-Reviewed Studies
Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product Concentrations
Plain-language guide to NCT07338214: phase 1 randomized trial of Petrelintide, 48 participants. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT07338214
- Phase
- phase 1
- Status
- completed
- Start
- 2025-12-17
- Completion (planned or actual)
- 2026-03-31
- Participants
- 48 (actual)
- Design
- randomized, open label (everyone knows who gets what), basic_science
- Conditions studied
- Obesity & Overweight
- Results posted
- not yet
What This Study Did, in Plain Language
What Was Tested
The trial (phase 1) is built around Petrelintide.
The main questions it aims to answer are: 1.
It had four arms (groups): Arm A (active comparator), Arm B (active comparator), Arm C (active comparator) and Arm D (active comparator).
The registry classes the interventions as drug.
More on the Plan
Approximately 48 participants are needed for the study.
Who Took Part
The registry lists 48 actual participants took part.
It was open to people of any sex aged from 18 years up to 64 years.
Healthy volunteers could join, not only people with the condition.
Examples of who could join: Signed and dated informed consent obtained before any study-related activities. Study-related activities are any procedures that would not have been done during normal management of the participant. BMI: ≥27.0 kg/m2, at screening and Day -1. Have sufficient venous access to allow cannulation for blood sampling as required by the protocol. Able and willing to comply with all study procedures.
The full record lists 4 inclusion and 25 exclusion criteria; among the exclusions: systolic bp ≥160 mmhg or diastolic bp ≥110 mmhg at screening; history of type 1 or type 2 diabetes mellitus; treatment with glucose-lowering agent(s) within 90 days prior to screening.
How the Study Was Run
Design: randomized, parallel-group and open-label.
The participants were allocated by chance, so the Petrelintide group and the comparison group should start out alike.
Groups ran in parallel: each of the participants stayed in one arm throughout.
Nothing was hidden in this open-label Petrelintide study: the participants and staff both knew the treatment.
It started in 2025-12-17 with completion listed for 2026-03-31.
It ran at 1 site in Germany.
Its stated primary purpose is basic science.
What This Means in Plain Language
Put simply, this is a phase 1, randomized trial of Petrelintide in 48 people.
The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.
More context: the Petrelintide compound page, all human trials.
Our Notes on the Compound
Petrelintide: A long-acting human amylin analog from Zealand Pharma, in phase 2 obesity trials.
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.